These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38264122)

  • 1. Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.
    Rahban M; Joushi S; Bashiri H; Saso L; Sheibani V
    Front Chem; 2023; 11():1325214. PubMed ID: 38264122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma.
    Nakada M; Kita D; Watanabe T; Hayashi Y; Hamada J
    Brain Tumor Pathol; 2014 Jul; 31(3):198-207. PubMed ID: 24399202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
    Brar HK; Jose J; Wu Z; Sharma M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
    Aldaz P; Arozarena I
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule tyrosine kinase inhibitors in glioblastoma.
    Kim G; Ko YT
    Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.
    Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC
    Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ
    J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
    Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
    Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.
    Paranthaman S; Goravinahalli Shivananjegowda M; Mahadev M; Moin A; Hagalavadi Nanjappa S; Nanjaiyah N; Chidambaram SB; Gowda DV
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33321953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
    Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
    Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.
    Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK
    Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
    Hu C; Dong X
    Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.
    Cioccio J; Claxton D
    Expert Opin Investig Drugs; 2019 Apr; 28(4):337-349. PubMed ID: 30775933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
    Qin A; Musket A; Musich PR; Schweitzer JB; Xie Q
    Neurooncol Adv; 2021; 3(1):vdab133. PubMed ID: 34806012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.